LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

Search

Certara Inc

Fermé

SecteurSoins de santé

8.14 -2.16

Résumé

Variation du prix de l'action

24h

Actuel

Min

8.09

Max

8.3

Chiffres clés

By Trading Economics

Revenu

3.5M

1.5M

Ventes

46K

105M

P/E

Moyenne du Secteur

123.143

105.69

BPA

0.14

Marge bénéficiaire

1.458

Employés

1,487

EBITDA

-21M

8.7M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+64.59% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-506M

1.4B

Ouverture précédente

10.3

Clôture précédente

8.14

Sentiment de l'Actualité

By Acuity

94%

6%

358 / 374 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Certara Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

17 nov. 2025, 18:59 UTC

Principaux Mouvements du Marché

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

17 nov. 2025, 23:40 UTC

Market Talk

Gold Consolidates Amid Mixed Signals -- Market Talk

17 nov. 2025, 23:34 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

17 nov. 2025, 22:58 UTC

Market Talk

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

17 nov. 2025, 22:46 UTC

Market Talk

Risk Assets Set to Have a Strong 2026 -- Market Talk

17 nov. 2025, 22:06 UTC

Acquisitions, Fusions, Rachats

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

17 nov. 2025, 22:02 UTC

Résultats

Trip.com Group 3Q Rev $2.6B >TCOM

17 nov. 2025, 22:02 UTC

Résultats

Trip.com Group 3Q Adj EPS $3.87 >TCOM

17 nov. 2025, 22:02 UTC

Résultats

Trip.com Group 3Q EPS $4.02 >TCOM

17 nov. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 nov. 2025, 21:40 UTC

Résultats

James Hardie Industries 2Q Adj EPS 26c >JHX

17 nov. 2025, 21:40 UTC

Résultats

James Hardie Industries 2Q Loss/Shr 10c >JHX

17 nov. 2025, 21:39 UTC

Résultats

James Hardie Industries 2Q Sales $1.29B >JHX

17 nov. 2025, 21:38 UTC

Résultats
Acquisitions, Fusions, Rachats

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov. 2025, 21:38 UTC

Résultats

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

17 nov. 2025, 21:10 UTC

Résultats

XP Inc. 3Q EPS BRL2.47 >XP

17 nov. 2025, 21:10 UTC

Résultats

XP Inc. 3Q Rev BRL4.67B >XP

17 nov. 2025, 20:20 UTC

Market Talk

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

17 nov. 2025, 20:12 UTC

Market Talk

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

17 nov. 2025, 20:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 nov. 2025, 20:09 UTC

Market Talk

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

17 nov. 2025, 19:29 UTC

Market Talk

Gold Slide Continues to Start Week -- Market Talk

17 nov. 2025, 19:16 UTC

Résultats
Acquisitions, Fusions, Rachats

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov. 2025, 18:20 UTC

Acquisitions, Fusions, Rachats

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

17 nov. 2025, 16:45 UTC

Acquisitions, Fusions, Rachats

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

17 nov. 2025, 16:16 UTC

Résultats
Acquisitions, Fusions, Rachats

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov. 2025, 16:15 UTC

Résultats

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

17 nov. 2025, 15:40 UTC

Acquisitions, Fusions, Rachats

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

17 nov. 2025, 15:22 UTC

Acquisitions, Fusions, Rachats

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

17 nov. 2025, 15:19 UTC

Market Talk

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Comparaison

Variation de prix

Certara Inc prévision

Objectif de Prix

By TipRanks

64.59% hausse

Prévisions sur 12 Mois

Moyen 13.71 USD  64.59%

Haut 16 USD

Bas 9 USD

Basé sur 9 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

9 ratings

4

Achat

5

Maintien

0

Vente

Score Technique

By Trading Central

11.27 / 12.79Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Very Strong Bullish Evidence

Long Terme

Strong Bullish Evidence

Sentiment

By Acuity

358 / 374Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Moyen

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat